Meeder Asset Management Inc Rigel Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$2.36 - $3.57 $7,103 - $10,745	-3,010 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$3.09 - $4.54 $7,755 - $11,395	-2,510 Reduced 45.47%	3,010 $13,000
Q1 2021 Apr 28, 2021	BUY	$3.35 - $4.93 $18,492 - $27,213	5,520 New	5,520 $19,000
Q4 2020 Feb 09, 2021	SELL	$2.35 - $3.74 $52,583 - $83,686	-22,376 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.27 - $3.0 $55,352 - $130,755	-43,585 Reduced 66.08%	22,376 $35,000
Q4 2019 Feb 13, 2020	BUY	$1.6 - $2.43 $46,576 - $70,737	29,110 Added 78.99%	65,961 $141,000
Q3 2019 Oct 17, 2019	BUY	$1.63 - $2.62 $57,631 - $92,635	35,357 Added 2366.6%	36,851 $68,000
Q2 2019 Aug 05, 2019	BUY	$2.02 - $2.61 $288 - $373	143 Added 10.58%	1,494 $4,000
Q4 2018 Jan 17, 2019	BUY	$2.08 - $3.36 $245 - $396	118 Added 9.57%	1,351 $3,000
Q3 2018 Nov 02, 2018	BUY	$2.6 - $3.59 $1,781 - $2,459	685 Added 125.0%	1,233 $0
Q1 2018 May 03, 2018	SELL	$3.54 - $4.54 $1,915 - $2,456	-541 Reduced 49.68%	548 $2,000
Q4 2017 Feb 02, 2018	BUY	$3.23 - $4.3 $3,517 - $4,682	1,089	1,089 $5,000

335K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.93B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.